After achieving statistically significant efficacy endpoints in a second Phase III study, Avanir Pharmaceuticals Inc. said it anticipates seeking regulatory approval later this year for Neurodex in the treatment of pseudobulbar affect, a syndrome that occurs with a number of neurodegenerative diseases. (BioWorld Today) Read More
